Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer

Cancer Biomarkers

Volumn 10, Issue 2, 2011, Pages 63-69

  Xu, Jianping ^a   He, Jiaying ^b   Yang, Huiyi ^b   Luo, Xiaodi ^b   Liang, Zhangmin ^b   Chen, Jiaxin ^b   Cai, Zhiping ^b   Xu, Jiasen ^b   Ren Heidenreich, Lifen ^b  

^a CANCER HOSPITAL   (China)

^b Guangzhou Technology Innovation Base   (China)

Author keywords

biomarker; Chinese patients; EGFR signaling pathway; liquidchip; non small cell lung cancers; somatic mutations

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; INOSITOL TRISPHOSPHATE 3 KINASE; K RAS PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CIGARETTE SMOKING; EXON; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SOMATIC MUTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SEX FACTORS; SMOKING; YOUNG ADULT;

EID: 84859324636     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0233     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70. (Pubitemid 32963812)
3. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10:4227-32.
4. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
5. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46. (Pubitemid 46621858)
6. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
7. Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 2008;5:209-17.
8. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004;305:1163-7. (Pubitemid 39100331)
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
10. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
11. Wu S, Zhu Z, He J, Luo X, Xu J, Ren-Heidenreich L. A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples. Clin Chem Lab Med 2010;48:1103-6.
12. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
13. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
14. Lìevre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992- 5.
15. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221-30.
16. Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 2008;60Suppl 2:S23-S30. (Pubitemid 351726034)
17. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int 2007;57:233-44. (Pubitemid 46595031)
18. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, et a1. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
19. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et a1. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2653-9.
20. Li Q, Zhao YL, Hao HJ, Li XH. EGFR gene mutation status among lung cancer patients in China. Zhonghua Zhongliu Zazhi 2007;29:270-3.
21. Chen WQ. Estimation of cancer incidence and mortality in China in 2004-2005. Zhonghua Zhongliu Zazhi 2009;31:664-8.
22. Li G, Luo X, He J, Zhu Z, Yu G, Qin H, et al. A novel liquid-chip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med 2010 Dec 1.
23. Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005;446:483-8.
24. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinic pathologic features. Clin Cancer Res 2006;12:1647-53.
25. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23. (Pubitemid 39665498)
26. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009;24:48-54.
27. Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, et al. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci 2007;98:985-91. (Pubitemid 46865381)
28. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006;54:209-15. (Pubitemid 44764916)
29. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999;91:2032-8.
30. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor genemutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11. (Pubitemid 39209661)
31. Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, Broderick S, et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2007;2:e426.
32. Sun LN, Luan HL, Zang FL, Wang M, Dong N, Guo Y, et al. Relationship between EGFR and K-ras mutations and clinic pathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer. Zhonghua Zhongliu Zazhi 2010;32:667-70.
33. Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, et al. Relationship between EGFR and K-ras mutations and clinic pathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer. J Thorac Oncol 2010;5:1734-40.
34. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRASmutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
35. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010;28:4616-20.
36. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6912-21.
37. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. (Pubitemid 40271173)
38. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
39. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007;58:324-8. (Pubitemid 350051507)
40. Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010;69:272-8.
41. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.